Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/22/2015 01/23/2015 01/26/2015 01/27/2015 01/28/2015 Date
420.81(c) 420.21(c) 423.77(c) 415.74(c) 408(c) Last
590 904 388 320 453 844 705 057 641 143 Volume
+0.65% -0.14% +0.85% -1.89% -1.86% Change
More quotes
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.Regeneron markets medicines for eye diseases, colorectal cancer and a rare inflammatory condition and... 
Sector
Pharmaceuticals
Calendar
02/10Earnings Release
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 2 796 M
EBIT 2014 1 159 M
Net income 2014 371 M
Finance 2014 1 087 M
Yield 2014 -
Sales 2015 3 491 M
EBIT 2015 1 644 M
Net income 2015 674 M
Finance 2015 1 955 M
Yield 2015 -
PER 2014 127,85
PER 2015 71,94
EV / Sales 2014 14,4x
EV / Sales 2015 11,3x
Capitalization 41 479 M
More Financials
Latest news on REGENERON PHARMACEUTICALS
01/28 REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Recommended for Approva..
01/27DJAmgen Profit Rises 27% on Higher Sales of Key Drugs -- Update
01/27 Investing in Westchester's biotech surge
01/27 SANOFI : and Regeneron Announce Praluent (alirocumab) Biologics License Applicat..
01/26DJSANOFI : FDA Grants Priority Review for Sanofi and Regeneron's Drug
01/26 REGENERON PHARMACEUTICALS : and Sanofi Announce Praluent™ (alirocumab) Bio..
01/23 REGENERON PHARMACEUTICALS : New Data from Regeneron Pharmaceuticals Inc. Illumin..
01/23 REGENERON PHARMACEUTICALS : Details Findings in Immunoglobulins (Efficacy and sa..
More news
Sector news Pharmaceuticals - NEC
01/28 SALIX PHARMACEUTICALS : to restate nearly 2 years of earnings after review
01/28DJSALIX PHARMACEUTICALS : to Restate 2013, Partial 2014 Results
01/28 NOVARTIS : announces study in NEJM showing Jakavi® was superior to standard ther..
Plus d'actualités du secteur Pharmaceuticals - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF